Jump to content



Recommended Posts

  • Replies 10k
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

Here is an interesting piece of navel gazing by one of the HC pumptards called waynesworld. Supposedly, PYC has the technology to get an oligonucleotide through the endosome layer and deliver into the cell. They even have a patent for it but not if you believe what ARWR says. However, I wonder if in fact it could be where BLT's ddRNAi comes to the fore. If so, the all time lows Benitec is trading at now could prove to be the steal of the century. If you consider, ALNY once traded at seven bucks and is now two hundred, ARWR once crashed to a buck something and is now in the sixties. Next cab off the rank could well be Benitec.


If morpholinos are the future of precision medicine it will be because the neutral charge helps to ensure they are free of off-target effects while the exquisite binding sequence ensures that they can uniquely target a selected gene. Oh, there is one small problem they are hopeless at getting into cells which is in fact, the drawback.

In light of the false dawn of gene therapy, the biotech that can harness the unique properties of morpholinos could well play a dominant role in the treatment of genetically defined disease.

Link to comment
Share on other sites

Hey! Look everyone. It's my old bile spewing mate 'loops. Back to doing what he does best. It's what makes this site so great.


A catastrophe coming to a cinema near you.


Asian contagion again. In the late nineties it precipitated the beginning of the dotcom bubble. This time it will be the bio-boom.


BLT could well be the steal of the century now.






Link to comment
Share on other sites

What a racket. Gotti was in the wrong game. Time has shown CSIRO made a blunder when they decided to save this company. Unless of course you are on payroll.


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On September 15, 2021, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Benitec Biopharma Inc. (the “Company”) approved discretionary bonus payments for Dr. Jerel Banks, the Company’s Executive Chairman and Chief Executive Officer, and Megan Boston, the Company’s Executive Director, in connection with their performance during the Company’s fiscal year ending June 30, 2021, in the amount of $225,000 for Dr. Banks and $111,340 for Ms. Boston. In addition, also on September 15, 2021, the Compensation Committee approved increases of Dr. Banks’ and Ms. Boston’s annual base salaries to $520,000 and $317,550, respectively, each effective as of September 16, 2021. Ms. Boston’ salary and bonus as reported in this Current Report on Form 8-K has been converted to U.S. dollars from Australian dollars using a conversion rate of AUD$1.00 to USD$0.73. In addition, the Compensation Committee has not changed the target annual discretionary bonus with respect to the Company’s fiscal year ending June 30, 2022 which are 50% and 40% of the base salary for each of Dr. Banks and Ms. Boston, respectively.


Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...